Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000947871-25-000112
Filing Date
2025-02-06
Accepted
2025-02-06 21:18:19
Documents
1
Period of Report
2025-02-06

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 7096
  Complete submission text file 0000947871-25-000112.txt   9249
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-42504 | Film No.: 25599017

Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022-4629
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022-4629 (212) 739-6400
OrbiMed Capital GP VIII LLC (Reporting) CIK: 0001845804 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-42504 | Film No.: 25599016

Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Issuer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)